NIJMEGEN, Netherlands--(BUSINESS WIRE)--Aiosyn, a software company that develops AI-powered pathology solutions, has announced the latest advancement in their automated quality control (QC) algorithm.
A study evaluated agreement between 10 AI digital pathology tools in assessing IHC-based HER2 expression and found the most variability in identifying HER2-low samples.
The proposed framework leverages weakly supervised multiple-instance learning (MIL) to reduce false-positive predictions. A novel morphology-based slide aggregation method is introduced to improve ...
Tumor microenvironment is a complex assembly of cancer cells, immune cells, stromal cells, and extracellular matrix components. Interactions between these components can significantly impact tumor ...
Ultivue today unveiled the expanded capabilities of its proprietary InSituPlex® DNA-barcoding and staining technology through comprehensive visualization of a whole slide 16-marker multiplex assay in ...
Real-world insights into cardiometabolic comorbidities and their role in triple-negative breast cancer outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract ...
Leica Biosystems, a global leader in anatomic and digital pathology solutions, today unveiled ChromoPlex III Triple Detection RUO, a chromogenic multiplex immunohistochemistry detection system ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results